DailyIQ
Last updated1 minute ago

KYMR·Kymera Therapeutics Inc.

$108.07
+2.09 (+1.97%)
High
$108.65
Open
$104.58
Market Cap
9.01B
52W High
$131.05
Low
$103.45
P. Close
$108.07
P/E
-
52W Low
$55.26
Fwd P/E
-20.84
DailyIQ Est.
$146.91
Inst. Ownership
0.2%
Short Interest
12.62%
Days to Cover
16.1
Technical Score (1D)
27
BEARISH
News Sentiment
73
BULLISH
On the 1D view, KYMR is trending bearish with a score of 27 and declining momentum. The SELL signal is technically clear, and price is deeply oversold. The nuance is sentiment: at 73, it's diverging from the price action, suggesting news flow hasn't caught up to the selling yet. That gap between technicals and sentiment doesn't invalidate the chart-based read, but it does add a wildcard. If sentiment eventually turns to confirm the weakness, the move likely has further to run. If sentiment holds and draws in buyers near $99.62, a base could form before a recovery toward $110.22. Position sizing should reflect the unresolved nature of this split. One tell worth tracking here is whether volume expands on tests of $99.62 or dries up instead - expansion suggests the technical read is starting to attract confirming sellers, while a fade suggests sentiment's steadier tone is the more accurate signal. Until that resolves, $110.22 remains the level that would invalidate the bearish case outright.
LOW TARGET
$111 +2.7%
2 analysts
MEAN TARGET
$139 +28.9%
10 analysts
HIGH TARGET
$180 +66.6%
20 analysts
PRICE RANGE
$111.00 - $180.00
SB / B / H / S / SS
10/16/4/1/1
DAILYIQ EST.
$146.91 (+35.9%)
Bought (1Y)
0 shares
$0
Sold (1Y)
3,638,684 shares
$391.4M
Mainolfi NelloChief Executive Officer
Option Exercise30,000 shares2026-10-01
Mainolfi NelloChief Executive Officer
Sell262 shares2026-10-01
Mainolfi NelloChief Executive Officer
Sell8,230 shares2026-10-01
Mainolfi NelloChief Executive Officer
Sell7,601 shares2026-10-01
Mainolfi NelloChief Executive Officer
Sell4,876 shares2026-10-01
31/ 100
Bearish
Overall: Bearish
✕Revenue declining year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-794.0%
Revenue CAGR
54.0%
Current Ratio
10.47x
Return on Equity
-19.7%

EPS

EstBeatMiss
$-1.33$-1.18$-1.02$-0.87$-0.71Q3'25Q3'26
QtrEstActual+/−
Q3'26$-1.26 - -
Q3'25$-0.78$-0.94-20.3%

Revenue

EstBeatMiss
$3M$3M$3M$3M$3MQ3'25Q3'26
QtrEstActual+/−
Q3'26$3M - -
Q3'25 - $3M -

Market Data

KYMR Stock Snapshot

BEARISH27/100
$108.07+$2.09 (2.0%)
Market cap
9.01B
Day range
$103.45 – $108.65
News sentiment
73/100 · Bullish
Analyst target
$139.32 (+28.9%)
Consensus
Buy · 32 analysts
52-week range+95.6% off low · -17.5% from high
$55.26$131.05
Price $108.07 DailyIQ Est. $146.91

The chart on KYMR has not stabilised: price is in the upper part of its 52-week range and the trend is still down. Company-specific news dominates here; sector-level flows matter less than for larger names.

Behaviour On Record

What KYMR's own history says about today's numbers

Realized volatility (21d)
35.1% 3rd pct
Below its peak
-14.8%
vs 200-day average
+18.0%
Up days (1y)
51%

Kymera Therapeutics Inc. is currently running 35.1% annualised volatility over the last 21 sessions. Measured against KYMR's own 6 years of daily returns rather than a market-wide average, that is the 3rd percentile — unusually subdued by its own history, against a typical reading of 64.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

KYMR is trading -14.8% below its running peak. Across 5 full years on file, its median worst-drawdown-in-a-year was -63.6%, and the deepest was -78.7% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +18.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 61st percentile — a somewhat wider gap than its own norm. Over the past year KYMR closed higher on 51% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 6 years of records, KYMR finished the month higher 3 of 6 times, with a median return of +6.1% and an average of +10.8%. Its strongest month historically has been November at +18.0% on average, its weakest May at -11.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: KYMR has opened more than 2% away from the prior close in 262 of 1,536 sessions (17.1% of the time), with the largest gaps running +23.0% and -12.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 1,537 daily closes between 2020-08-21 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against KYMR's own 6-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of KYMR's sector?

Kymera Therapeutics Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, KYMR ranks 9th of 15 tracked industries, lagging.

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
73
Industry rank
#9 of 15

Options Market

What is the options market pricing for KYMR?

CallsPuts

For Kymera Therapeutics Inc.'s nearest expiry (2026-10-16, 9 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.58), with at-the-money implied volatility around 80.7%. The options market is pricing roughly a ±10.7% move by that expiry — a range of about $96.48–$119.52.

Put/call ratio (2026-10-16)
0.58
ATM implied volatility
80.7%
Total open interest
57
Expected move by 2026-10-16
±10.7% ($96.48–$119.52)

Analyst Rating Changes

Are analysts turning bullish or bearish on KYMR?

Citigroup most recently reiterated its rating on Kymera Therapeutics Inc. to Buy on Oct 5, 2026 with a price target of $150 (from $135). Over the last 90 days, coverage has run 1 upgrade against 1 downgrade, a net mixed lean.

Latest action
Citigroup — Buy
90-day upgrades
1
90-day downgrades
1
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 5, 2026CitigroupMaintainedBuy$135 → $150
Sep 22, 2026StifelMaintainedBuy$132 → $152
Sep 14, 2026B of A SecuritiesMaintainedBuy$123 → $144
Sep 10, 2026Wolfe ResearchUpgradePeer Perform → Outperform-
Aug 31, 2026GuggenheimMaintainedBuy$135 → $170
Aug 27, 2026Wells FargoMaintainedOverweight$116 → $151
Aug 6, 2026BarclaysMaintainedOverweight$133 → $139
Jul 30, 2026Deutsche BankInitiatedHold$120
Jul 28, 2026GuggenheimMaintainedBuy$125 → $135
Jul 16, 2026MizuhoMaintainedOutperform$120 → $140
Jul 13, 2026RBC CapitalDowngradeOutperform → Sector Perform$106 → $115
Jun 30, 2026B of A SecuritiesMaintainedBuy$110 → $125

News Sentiment Analysis

Sentiment gathered from recent headlines

73/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Citigroup analyst Geoff Meacham upgraded Kymera Therapeutics to a Buy rating and increased the price target from $135 to $150. The upgrade reflects confidence in the company’s pipeline and recent clinical progress. The higher target suggests a bullish outlook for the stock’s valuation. This move is expected to influence investor sentiment and trading activity. The rating change signals a positive market view of Kymera’s prospects.
What did this article say?
Stifel analyst Alex Thompson has upgraded Kymera Therapeutics to a Buy rating and increased the price target from $132 to $152. The upgrade reflects confidence in the company’s pipeline and recent clinical data. The higher target suggests a bullish outlook on Kymera’s growth prospects.
What did this article say?
Kymera Therapeutics (KYMR) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, outlining recent progress in its oncology pipeline and upcoming clinical milestones. The company emphasized the status of its lead candidate in phase 2 trials, noting enrollment targets and projected timelines. Management reiterated its commitment to regulatory milestones and discussed potential partnership opportunities. No new financial guidance or material corporate actions were disclosed, suggesting a routine update rather than a catalyst.
What did this article say?
B of A Securities upgraded its view on Kymera Therapeutics, raising the price target from $123 to $144 while maintaining a Buy rating. The move reflects confidence in the company’s pipeline and recent clinical milestones. The upgrade signals a bullish outlook for investors, suggesting potential upside if the company continues to progress its drug development program.
What did this article say?
Bank of America upgraded Kymera Therapeutics’ price target from $123 to $144, reflecting a more optimistic view of the company’s prospects. The new target aligns with a buy rating and an average analyst consensus of $137.73. The upgrade signals confidence in Kymera’s pipeline and potential market positioning.
What did this article say?
Kymera Therapeutics (KYMR) participated in Citigroup’s Biopharma Back to School Summit on September 10, 2026, delivering a presentation on its ongoing research and development pipeline. The event served as a platform for the company to update investors and industry peers on progress, without announcing new financial guidance or regulatory milestones. The presentation was largely informational, reflecting routine engagement rather than a material corporate development.
What did this article say?
Wolfe Research upgraded Kymera Therapeutics from Peer Perform to Outperform, citing robust clinical data and a favorable pipeline outlook. The analyst highlighted recent positive trial results for the company’s lead oncology asset and noted an expanding commercial strategy. This upgrade signals renewed confidence in Kymera’s growth trajectory and may influence short‑term valuation expectations.
What did this article say?
Kymera Therapeutics (KYMR) posted a Q2 2026 loss of $0.62 per share, narrower than estimates, while revenue jumped to $65 million from $11.5 million a year earlier, exceeding consensus. The growth was driven entirely by collaboration agreements, notably a $45 million option fee from Gilead for its KT‑200 candidate. The company’s partnership pipeline and improved profitability suggest a strong upside trajectory ahead of the next earnings release.
What did this article say?
Kymera Therapeutics (KYMR) has completed enrollment in its BROADEN2 phase IIb study of KT-621 for atopic dermatitis earlier than planned, with top‑line data now expected by year‑end 2026. The company also expanded the study to include adolescents and is preparing to launch phase III trials by mid‑2027. These milestones suggest a faster path to regulatory approval and potential commercial launch, positioning KYMR favorably in the atopic dermatitis and asthma markets.
What did this article say?
Kymera Therapeutics will attend several investor conferences in September, providing an opportunity for management to discuss company updates and future plans.

Technical Analysis

Real-time indicators across multiple timeframes

27
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
1 tracked managers · $20.06M combined position · 0 adding, 0 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Citadel Advisors LLC• Hold174,9550.21%$20.06M2026-09-02
Q2 2026 flow:175.0K sh bought ($20.06M)0 sh sold ($0)net +175.0K sh (+$20.06M)